(Q79845789)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16823384%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

title

Linking the PANSS, BPRS, and CGI: clinical implications (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16823384%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16823384%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

4

Werner Kissling

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16823384%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1

Stefan Leucht

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16823384%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

author name string

John M Kane

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16823384%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Eva Etschel

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16823384%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Johannes Hamann

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16823384%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

publication date

5 July 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16823384%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

published in

Neuropsychopharmacology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16823384%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16823384%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16823384%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

page(s)

2318-2325

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16823384%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.npp.1301147

26 December 2019

exact match

0 references

cites work

Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301147

7 January 2021

Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301147

7 January 2021

Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301147

7 January 2021

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301147

7 January 2021

Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301147

7 January 2021

Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301147

7 January 2021

Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301147

7 January 2021

A meta-analysis of the efficacy of second-generation antipsychotics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301147

7 January 2021

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301147

7 January 2021

Clinical implications of Brief Psychiatric Rating Scale scores

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301147

7 January 2021

What does the PANSS mean?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301147

7 January 2021

Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301147

7 January 2021

Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301147

7 January 2021

Risperidone in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301147

7 January 2021

Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301147

7 January 2021

Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301147

7 January 2021

Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301147

7 January 2021

Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301147

7 January 2021

Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301147

7 January 2021

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301147

7 January 2021

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301147

7 January 2021

Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1301147

7 January 2021